{"id":723,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"tirzepatide-surmount-1-2539-adults-72-weeks","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/de\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","title":{"rendered":"Tirzepatide SURMOUNT-1: 2,539 Erwachsene \u00fcber 72 Wochen"},"content":{"rendered":"<h2>Warum SURMOUNT-1 eine n\u00fctzliche Ankerstudie ist<\/h2>\n<p>SURMOUNT-1 ist eine gro\u00dfe, randomisierte Phase-3-Studie mit einer Placebogruppe und vorab festgelegten koprim\u00e4ren Endpunkten. Es unterst\u00fctzt daher eine st\u00e4rkere Diskussion \u00fcber klinische Beweise als mechanistische Behauptungen oder unkontrollierte Beobachtungen. Das Papier berichtet auch \u00fcber den vollst\u00e4ndigen Satz randomisierter Dosisgruppen und nicht \u00fcber eine selektiv ausgew\u00e4hlte Zahl.<\/p>\n<h2>Bev\u00f6lkerung und Endpunkte<\/h2>\n<p>An der Studie nahmen Erwachsene mit einem Wert von mindestens BMI 30 oder mindestens 27 mit einer gewichtsbedingten Komplikation teil. Diabetes wurde ausgeschlossen. Die Teilnehmer wurden zu gleichen Teilen in drei Tirzepatid-Gruppen oder Placebo eingeteilt. Der Behandlungsschema-Sch\u00e4tzwert bewertete die Ergebnisse unabh\u00e4ngig vom Behandlungsabbruch in der Intention-to-Treat-Population.<\/p>\n<h2>Ergebnisse im Kontext<\/h2>\n<p>Alle drei Tirzepatid-Gruppen unterschieden sich hinsichtlich der gemeldeten Gewichtsendpunkte von Placebo. In der Arbeit werden auch gastrointestinale unerw\u00fcnschte Ereignisse als am h\u00e4ufigsten aufgef\u00fchrt, im Allgemeinen w\u00e4hrend der Eskalation, und es werden Abbruchprozents\u00e4tze f\u00fcr jede randomisierte Gruppe angegeben. Die Sichtbarkeit dieser Nenner und Daten zu unerw\u00fcnschten Ereignissen verhindert eine ausschlie\u00dfliche Zusammenfassung der Wirksamkeit.<\/p>\n<div class=\"pfm-case-callout\"><strong>Vergleichsgrenze:<\/strong> SURMOUNT-1 war keine Retatrutid-Studie und kann kein direktes Retatrutide-gegen-Tirzepatide-Ranking liefern. Die versuchs\u00fcbergreifenden Prozents\u00e4tze stammen aus verschiedenen Protokollen und Entwicklungsstadien.<\/div>\n<h2>Unterscheidung von Fertigarzneimitteln<\/h2>\n<p>Klinische Ergebnisse eines von einer Aufsichtsbeh\u00f6rde gepr\u00fcften Fertigarzneimittels k\u00f6nnen nicht auf Material \u00fcbertragen werden, das den gleichen Namen hat, aber nicht \u00fcber die gleiche Formulierung, das gleiche Verabreichungssystem, die gleichen Freigabespezifikationen und die gleichen Qualit\u00e4tskontrollen verf\u00fcgt. Diese Unterscheidung ist Teil der Beweisaufnahme und keine Fu\u00dfnote.<\/p>","protected":false},"excerpt":{"rendered":"<p>Eine strukturierte Lekt\u00fcre der SURMOUNT-1-Phasenstudie 3 unter Beibehaltung des randomisierten Designs, der Vier-Gruppen-Ergebnisse, der Abbruchdaten und der Unterscheidung zwischen einem zugelassenen Fertigarzneimittel und Forschungsmaterial.<\/p>","protected":false},"author":0,"featured_media":851,"template":"","class_list":["post-723","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tirzepatide SURMOUNT-1 Trial: 2,539 Adults<\/title>\n<meta name=\"description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\" \/>\n<meta property=\"og:description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"name\":\"Tirzepatide SURMOUNT-1 Trial: 2,539 Adults\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tirzepatide SURMOUNT-1-Testversion: 2,539 Erwachsene","description":"Eine strukturierte Lekt\u00fcre der SURMOUNT-1-Phasenstudie 3 unter Beibehaltung des randomisierten Designs, der Vier-Gruppen-Ergebnisse, der Abbruchdaten und der Unterscheidung zwischen einem zugelassenen Fertigarzneimittel und Forschungsmaterial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_locale":"de_DE","og_type":"article","og_title":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks","og_description":"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.","og_url":"https:\/\/nhdbio.com\/de\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","name":"Tirzepatide SURMOUNT-1-Testversion: 2,539 Erwachsene","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Eine strukturierte Lekt\u00fcre der SURMOUNT-1-Phasenstudie 3 unter Beibehaltung des randomisierten Designs, der Vier-Gruppen-Ergebnisse, der Abbruchdaten und der Unterscheidung zwischen einem zugelassenen Fertigarzneimittel und Forschungsmaterial.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/723\/revisions"}],"predecessor-version":[{"id":728,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/723\/revisions\/728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/851"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}